Implementation of a web-based tool for patient medication self-management: the Medication Self-titration Evaluation Programme (Med-STEP) for blood pressure control

Richard W Grant
Division of Research, Kaiser Permanente Northern California, Oakland, USA

Jennifer C Pandiscio
Hannah Pajolek
Mongan Institute for Health Policy, Massachusetts General Hospital, Boston, USA

Alyssa Woulfe
Alexandra Pelletier
Partners Center for Connected Health, Boston, USA

Joseph Kvedar
Partners Center for Connected Health, Boston and Harvard Medical School, Boston, USA

Elyse R Park
Mongan Institute for Health Policy, Massachusetts General Hospital, Boston, and Harvard Medical School, Boston, USA

ABSTRACT

Background Informatics tools may help support hypertension management.

Objective To design, implement and evaluate a web-based system for patient anti-hypertensive medication self-titration.

Methods Study stages included: six focus groups (50 patients) to identify barriers/facilitators to patient medication self-titration, software design informed by qualitative analysis of focus group responses and a six-month single-arm pilot study (20 patients) to assess implementation feasibility.

Results Focus groups emphasised patient need to feel confident that their own primary care providers were directly involved and approved of the titration protocol. Physicians required 3.3 ± 2.8 minutes/patient to create individualised six-step medication pathways for once-monthly blood pressure evaluations. Pilot participants (mean age of 51.5 ± 11 years, 45% women, mean baseline blood pressure 139/84 ± 12.2/7.5 mmHg) had five medication increases, two non-adherence self-reports, 52 months not requiring medication changes, 24 skipped months and 17 months with no evaluations due to technical issues. Four pilot patients dropped out before study completion. From baseline to study completion, blood pressure decreased among the 16 patients remaining in the study (8.0/4.7 mmHg, p = 0.03 for both systolic and diastolic pressures).

Conclusions Lessons learned included the benefit of qualitative patient analysis prior to system development and the feasibility of physicians designing individual treatment pathways. Any potential
Introduction

Almost one-third of US adults have been diagnosed with hypertension. Despite the availability of a spectrum of potent medications, 63% of the US hypertensive population remains suboptimally controlled. Poor blood pressure control, in turn, has been shown to increase the risk for myocardial infarction, renal disease, stroke and premature death. The failure to satisfactorily address hypertension management within our current healthcare system requires the development of novel care strategies.

To date, most interventions to transform care have focused primarily on clinicians and clinical practice systems and have had only marginal benefit. The patient, however, is increasingly recognised as the most important member of the healthcare team. Prior research has demonstrated that increasing patients’ involvement in their care improves control of chronic diseases such as hypertension and diabetes. A relatively untested innovation in chronic disease management is to expand the patient’s role in the medication titration process.

There are few published trials of medication self-titration for blood pressure control and limited experience in implementing such approaches using a health IT infrastructure. We hypothesised that enabling patients to implement a predefined hypertension medication treatment pathway designed by their primary care physician (PCP) would result in more timely treatment changes and more effective blood pressure control. In this report, we describe the design, implementation and feasibility evaluation of the Medication Self-titration and Evaluation Program (Med-STEP) for blood pressure control.

Methods

Conceptual framework for the Med-STEP system

A review of the published literature indicated two prevalent barriers to optimal hypertension management: (1) clinical inertia (the observation that medication changes frequently are not made during clinic visits despite elevated blood pressure levels); and (2) lack of patient engagement with treatment plans. To address these two barriers, we conceived of a system in which: (1) a sequence of medication changes (medication treatment pathway) prespecified by the patient’s PCP could be followed independent of clinic visits; and (2) patients directed their own medication management through home blood pressure self-monitoring, health IT-supported monthly evaluation of blood pressure results and medication self-titration based on PCP-defined medication treatment pathways.

Based on this conceptual framework, we created the Med-STEP intervention. The development process had three sequential phases: (1) focus group discussions with patients to identify both perceived benefits and concerns related to the self-titration of chronic disease medications; (2) development of the Med-STEP web-based interface linked to an existing system of home blood pressure electronic data collection; and (3) piloting the system in a single primary care practice to assess its feasibility prior to wider implementation.

Patient focus groups

Six 90-minute patient focus groups were conducted from March 2008 to May 2008. Patients diagnosed with both diabetes and hypertension were recruited from the primary care practices of the Massachusetts General Hospital Practice-based Research Network, Boston, MA. All patients were currently taking hypertension and/or diabetes-related medicines. After eliciting their views regarding their experiences with starting and adjusting medications over time, participants were asked their views about adjusting their own medical regimens. To help convey the concept, we showed participants a paper-based example of a medication treatment pathway for a hypothetical patient depicting a sequence of potential future medication changes over time (Figure 1). Group interviews were recorded digitally and transcribed for qualitative content analysis by three coders using NVivo 7.0 software (SdG Associates, London, UK). The moderator reviewed the transcripts for accuracy. All participants received a $40 stipend.

Keywords: blood pressure, home monitoring, hypertension, medication adjustment, medication safety, self-management
Med-STEP system development

Our health system has an existing informatics platform to help manage home blood pressure readings (Blood Pressure Connect). Components of this platform include: automated data upload and central storage from home blood pressure cuffs, a patient web-based interface that graphically represents blood pressure trends, a provider web-based interface that lists patients enrolled in the Blood Pressure Connected health programme and allows review of individual patient results, and a secure messaging system for patients and providers.

With this platform as our starting point, we added two novel components: a stand-alone medication treatment pathway entry form to input the PCP-defined treatment algorithms (blood pressure thresholds, medication steps, and any corresponding laboratory safety monitoring tests if required, see Figure 2); and a new ‘my treatment pathway’ page within the existing patient Blood Pressure Connect web application to guide patients through the process of blood pressure medication adjustment over time (see Figure 3). As described in the Results, development of these two new components was informed by the results of the focus group analysis.

Pilot clinical study

To assess the feasibility of the Med-STEP intervention, we collaborated with a primary care practice within our hospital network that expressed interest in interventions to address quality of hypertension management. The five PCPs in this practice all endorsed the Med-STEP approach and referred suitable patients to our study staff. In addition to PCP referrals, we also used available electronic registry data to identify other potentially eligible patients. Patient eligibility criteria included: age > 18 years, elevated blood pressure (> 140/90 mmHg when last measured, or on treatment and referred by PCP), prescribed 0 or 1 blood pressure medications, access to an internet connection and a compatible analogue telephone land line and willingness to adjust own medicines. Patients participating in the original focus group sessions were not included in the pilot trial.
The study coordinator met eligible subjects at the practice to explain the Med-STEP intervention and obtain written informed consent. At this research visit, subjects also completed a baseline survey designed to assess their views about hypertension management.

Once a study participant had successfully logged-on to the website from home and had uploaded at least one blood pressure reading, a medication treatment pathway was defined by the subject’s PCP. The principal investigator collected the following data from the PCP to be entered into the medication treatment pathway algorithm entry form (Figure 2): the minimum number of home blood pressure readings required before a change would be considered; PCP-designated blood pressure thresholds for increasing or decreasing the regimen; and a sequence of four to six medication changes (and any corresponding laboratory testing) that this patient would follow. These pathways all began with ‘Step 1’ (no medicines) and progressed in single management increments (e.g. dose adjustment or addition of new medicine) up to ‘Step 6’. Each patient had a unique pathway and could be enrolled in the study starting at any step.

During the first week for each calendar month of the six-month clinical trial, patients used a home blood pressure monitoring device to automatically upload blood pressure readings. Based on the PCP-defined algorithm, the web-based user interface advised patients to increase, decrease or remain at their current medication treatment pathway step. If a medication change was advised, a prescription was manually sent to the pharmacy, the medical record was manually updated, and the research coordinator followed up with the patient. Pilot trial participants received a $75 stipend. All phases of the study were approved by the Massachusetts General Hospital Institutional Review Board.

**Figure 2** Screenshot of the ‘medication treatment pathway’ algorithm entry form used to record PCP-planned medication changes
Patient focus groups and software development

Most focus group participants had a positive impression of the concept underlying the Med-STEP intervention. The following major themes emerged from the discussions as benefits of medication self-titration.

• **Awareness**: Participants reported that knowing the sequence of planned medication steps was very appealing because it would inform them of their disease process (e.g. ‘... you know whether you’re on the right track or not’) and could reduce anxiety (e.g. ‘... it eliminates the ... anxiety you have when the doctor suddenly announces something to you’).

• **Engagement**: Several participants suggested that the programme would make them feel more responsible for their hypertension management. One man stated, ‘It’s becoming participatory medicine’. Other similar comments included: the programme would ‘help me to take more responsibility for myself, to take better care of myself’ and ‘We are, after all, all managers of our own health issues ... And this gives us the chance to do that’.

• **Motivation**: Many participants expected that the programme would ultimately lead to better disease control through increased patient motivation. As one participant declared, the programme would provide ‘... incentive to try to get down to that Step 1’.

• **Convenience**: Another participant suggested that, since patients would make medication adjustments between appointments with their physicians, the programme would eliminate some delay in care between visits: he noted, ‘Because at times, one is waiting for the doctor to help ...’; One person said, ‘I would like if it ... eliminated two out of four appointments’.

Because of these patient-reported benefits, we were encouraged to proceed with building the Med-STEP system. However, despite the many positive comments, participants voiced five important concerns that were key to informing the development process. Table 1 lists the five major concerns (detrimental effect on doctor–patient relationship, variability of individual blood pressure readings, difficulty in correctly following a pathway, concern about medication side effects and the effort required to participate) and the corresponding design features we implemented to address the concern. One major issue raised by participants was the concern that enrolling in a medication self-management programme could interfere with the current relationship the patients enjoyed with their PCPs. An innovative feature of our design in response to this concern was the implementation of individualised medication treatment pathways that...
were authored by each patient’s PCP rather than using a single, external treatment algorithm.

The Med-STEP pilot study

Pilot study participants were recruited both by PCP referral and by direct invitation (see Figure 4 for patient flow diagram). Of 48 patients successfully contacted by phone, 20 (42%) consented to participate (mean age 51.5 years, 45% women, 20% non-white ethnicity; Table 2). Participants were diagnosed with hypertension for a mean of 6.0 ± 4.3 years, and 17 (85%) were on medicines prior to enrolling in the pilot. The two factors from the baseline survey that patients most often cited as motivating their desire to improve their hypertension management were ‘to avoid future medical problems’ (all 20 subjects rated this ‘very important’) and ‘to live a longer and healthier life’ (19 subjects rated this ‘very important’).

Medication treatment pathways were obtained from the five PCPs managing these 20 study subjects. Excluding the first ‘training’ pathway, PCPs required 3.3 ± 2.8 minutes to designate six-step medication pathways for each patient. These pathways were very patient specific, with 19 different sequences created for the 20 subjects.

Med-STEP pilot results

The 20 participants provided 100 patient-months of data for the Med-STEP algorithm (four patients withdrew before completing all six months). Patients successfully evaluated their medication treatment pathways for 59 study months, resulting in five increased medication dose recommendations (for three patients), two patient self-reports of non-adherence, and 52 readings that did not require medication changes. Pathways were not evaluated for 41 patient-months either because patients chose not to access the system (24 months) or due to system technical issues (17 months). Common technical problems included: digital voicemail interference with uploading blood pressures (n = 5), faulty modems (n = 4) and web password problems (n = 4). Of interest, for the three patients with recommendations to ‘step-up’ in their medication treatment pathway, all three had successful regimen intensification when instructed the first time, but neither of the two who were instructed to step-up the second time had successful regimen changes (one subject declined to increase her dose again and the other

<table>
<thead>
<tr>
<th>Concern</th>
<th>Design features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detrimental effect on doctor–patient relationship</td>
<td>1. Participant continues to see his/her physician at usual intervals (i.e. home monitoring would not take the place of visits) 2. PCPs participate in selection of programme participants 3. Each participant’s ‘medication treatment pathway’ is designed by his/her own PCP</td>
</tr>
<tr>
<td>Variability in blood pressure readings</td>
<td>1. Home monitoring with treatment decisions based on the average of several readings (minimum number chosen by PCP) 2. Automated blood pressure cuff (reduces user errors associated with manual measurement)</td>
</tr>
<tr>
<td>Correctly following pathway</td>
<td>1. Automated uploads of blood pressure measurements 2. Pathway uploaded to website 3. Algorithm run by computer 4. Verified by physician principal investigator</td>
</tr>
<tr>
<td>Medication side-effects</td>
<td>1. All medications chosen by the PCP 2. Possible side-effects listed in the pathway; instructed to call primary care practice about any side-effects 3. No increased risk from side-effects relative to usual care</td>
</tr>
<tr>
<td>Too much effort/doesn’t want responsibility</td>
<td>1. Highly selective programme 2. Automated home monitoring device and website pathway 3. Subject continues to see his/her physicians at usual intervals (i.e. home monitoring would not take the place of visits)</td>
</tr>
</tbody>
</table>
subject did not obtain the laboratory testing required prior to making the change).

There was a significant decrease in blood pressure among the 16 participants who completed the study (systolic blood pressure declined by 8.0 mmHg, \( p = 0.03 \); diastolic blood pressure declined by 4.7 mmHg, \( p = 0.025 \)). The three subjects with medication increases had an average blood pressure decline of 8.7/5.7 mmHg.

End-of-study surveys were collected from 18 participants. Most of these patients (16/18) agreed that the system was useful to help them manage their hypertension and 17/18 would recommend the system to others, although several participants reported their frustration with technical issues.

**Discussion**

We designed a web-based system linking home blood pressure monitoring to PCP-defined medication treatment pathways with the goal of improving blood pressure control. In a six-month pilot study, we found that implementation of the system was feasible but was limited by technical issues, patient reluctance to make changes or self-monitor and relatively low enrolment rates.

Although we showed the system to be feasible for blood pressure management, there were several key lessons learned that we believe are crucial for subsequent efforts to generalise this model of care.

**Patient–PCP connection**

In response to concerns raised by many of our focus group participants, we designed our programme to
strengthen rather than obscure the PCP's role. To achieve this goal, we opted to have PCPs design their patients' medication treatment pathways rather than rely on published algorithms. We found that PCPs were able to quickly and efficiently design unique pathways for each patient. This process also increased PCP and patient confidence in the programme. Pilot participants confirmed the importance of their PCP knowing that changes were being made. Our results suggest that this strategy may have advantages over using predefined treatment algorithms.

Limitations of the ‘patient engagement’ model

It has become widely accepted that increasing patient engagement with their care can improve clinical outcomes.26,27 While our study does not disprove this principle, we found that several subjects were reluctant to make changes even when indicated by their PCP-designed medication treatment pathways. This result suggests that even among consented study participants, many patients with asymptomatic diseases conveying relatively minor short-term clinical risks may not feel comfortable making repeated medication changes over a relatively short time. It must be noted that patients in our pilot study were not directly involved in the design of their medication pathways. Thus, while pilot participants had an active role in their hypertension management, the Med-STEP pilot did not represent a truly collaborative, shared decision-making model of care as recommended by the chronic care model. Future research is needed into the potential benefits (and increased time requirements) of a shared decision-making approach.

Technology failings

Because of issues with connectivity and password access, several participants experienced repeated tech-
technical problems, which led to withdrawal from the programme. This is not a great insight, but it underscores the importance of implementing simple, high-fidelity health IT systems to avoid losing patient or provider buy-in.

Workflow

The primary care practice and associated PCPs were willing to participate in the study because the research team assumed responsibility for many of the tasks generated by the programme (e.g. programme enrolment and patient education, updating the clinic record when changes were made, ordering and following up the results of safety labs triggered by medication changes, and sending new prescriptions to the patient’s pharmacy). While several of these functions could be automated in a more advanced version of the programme, the clinical benefit has to justify the model of non-visit-based care. With health payment reform, newer models of care (e.g. accountable care organisations) may be amenable to this programme. In addition, current care systems may lack the flexibility required for more collaborative care given the additional time that would be required to create medication pathways using a PCP-patient shared decision-making approach.

To date, there have been two small pilot studies of patient medication self-titration and one recent, large randomised trial. The earliest study randomised 31 hypertensive subjects to home blood pressure monitoring and medication self-titration using a paper-based algorithm. This initial pilot, conducted in 1997, reported modest blood pressure benefits but did not appear to be subsequently evaluated or adopted on a larger scale. A second pilot study conducted more recently in France focused on feasibility and safety. This short-term study (only eight weeks) combined home blood pressure monitoring, telemedicine contact with the research team and a single titration protocol for all participants. Patients on non-study medicines at study entry were converted to the study protocol. The authors report overall satisfaction with the programme by participants and decline from baseline in mean blood pressure by eight weeks.

Most recently, McManus et al reported the results of a large randomised trial (telemonitoring and self-management in the control of hypertension [TASMINH2]) conducted in the UK involving 24 primary care practices and 527 participants with hypertension (blood pressure > 140/90 mmHg despite anti-hypertensive treatment). As in our study, medication titration parameters were defined by patients’ PCPs, although in TASMINH2 the treatment pathways were limited to two medication titrations over the 12-month study and changes were only made if blood pressure readings were elevated for two consecutive months. The protocol of medication adjustment was less aggressive than the monthly assessments in the Med-STEP study. Based on exit interviews from Med-STEP participants, we believe that fewer changes over a greater period of time (as with TASMINH2) may actually improve patient participation. Implementation of the TASMINH2 trial was resource-intensive. Researchers invited 7637 patients to participate, and screened 1650 patients accepting the invitation to randomise 527 participants (of whom only 480 were ultimately included in the final analysis). Participants each received two intensive training sessions prior to enrolment to ensure competence in blood pressure measurement and data transfer via modem. Researchers also scheduled visits at 6 and 12 months for data collection.

The results from our study and from TASMINH2 and other pilot trials lead to several general conclusions and suggest important next steps. The data show that patients who can successfully self-titrate their blood pressure medications will likely have improved blood pressure control. Given the high prevalence and significant clinical impact of hypertension, efforts to implement this approach among patients with inadequately controlled blood pressure deserve strong consideration. As with many innovations that involve new technology and new patterns of care, however, translation of this concept into usual care will require addressing significant barriers to change such as current visit-based payment mechanisms, provider workflow and team composition, reliability of technology, and patient willingness to adopt a greater role in their disease management.

ACKNOWLEDGEMENTS

The authors wish to thank and acknowledge the efforts of the providers and staff at the MGH Back Bay Health Center.

FUNDING

This study was funded in part by the National Institute of Diabetes and Digestive and Kidney Diseases (R03 DK080183) and by a Partners IS Research Grant award.

CONFLICTS OF INTEREST

The authors declare no competing interests.

REFERENCES

1 Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ and Sorlie P. The burden of adult hypertension in the United
ADDRESS FOR CORRESPONDENCE

Richard W Grant
Division of Research
Kaiser Permanente Northern California
2101 Webster St
Oakland
CA 94612
USA

Accepted April 2012